Athenex Inc (NASDAQ:ATNX) Director Jinn Wu bought 2,500 shares of the stock in a transaction dated Thursday, September 6th. The stock was purchased at an average cost of $16.09 per share, for a total transaction of $40,225.00. Following the acquisition, the director now owns 266,708 shares in the company, valued at approximately $4,291,331.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Jinn Wu also recently made the following trade(s):
- On Monday, August 20th, Jinn Wu bought 5,000 shares of Athenex stock. The stock was purchased at an average cost of $17.20 per share, for a total transaction of $86,000.00.
NASDAQ:ATNX traded up $0.16 during mid-day trading on Friday, reaching $15.84. 365,354 shares of the company were exchanged, compared to its average volume of 257,725. Athenex Inc has a 12 month low of $13.28 and a 12 month high of $20.90. The firm has a market cap of $1.04 billion, a P/E ratio of -6.83 and a beta of -1.75.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). Athenex had a negative return on equity of 73.37% and a negative net margin of 122.29%. The company had revenue of $11.57 million for the quarter. analysts expect that Athenex Inc will post -2 EPS for the current year.
A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in Athenex by 177.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 163,893 shares of the company’s stock worth $3,058,000 after acquiring an additional 104,918 shares during the last quarter. MetLife Investment Advisors LLC bought a new stake in Athenex during the 2nd quarter worth about $376,000. Metropolitan Life Insurance Co. NY bought a new stake in Athenex during the 2nd quarter worth about $266,000. Bank of America Corp DE grew its holdings in Athenex by 34.4% during the 2nd quarter. Bank of America Corp DE now owns 56,822 shares of the company’s stock worth $1,060,000 after acquiring an additional 14,530 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in Athenex during the 2nd quarter worth about $294,000. 19.82% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Athenex from a “hold” rating to a “buy” rating in a report on Friday, July 6th. ValuEngine lowered shares of Athenex from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Finally, Zacks Investment Research lowered shares of Athenex from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Athenex presently has an average rating of “Hold” and an average target price of $26.71.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
See Also: Book Value Per Share – BVPS
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.